Companies Opus Genetics
Opus Genetics (IRD): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Opus Genetics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,667,353FY2023
- $889,238FY2024
- $1,493,383FY2025
CEO total pay was $1,493,383 in fiscal 2025, up from $889,238 in fiscal 2024.
FY2025: salary $598,000 · bonus $0 · stock awards $307,548 · option awards $212,045
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| George Magrath | $598,000 | $0 | $307,548 | $212,045 | $361,790 | $0 | $14,000 | $1,493,383 |
| Chief Executive Officer | ||||||||
| Ashwath Jayagopal | 416,000 | 50,000 | 48,825 | 33,663 | 205,920 | 0 | 10,440 | 764,848 |
| Chief Scientific and Development Officer | ||||||||
| Joseph Schachle | 416,000 | 0 | 48,825 | 33,663 | 205,920 | 0 | 14,000 | 718,408 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| George Magrath | $1,493,383 | $889,238 | $2,667,353 | ↑ +604,145 |
| Ashwath Jayagopal | 764,848 | 1,242,154 | — | ↓ −477,306 |
| Joseph Schachle | 718,408 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our current executive compensation program is intended to align executive compensation with our business objectives and to enable us to attract, retain and reward executive officers who contribute to our long-term success.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Anderson Pay Advisors, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joseph Schachle | RSU | 52,500 | — | $105,525 |
| Joseph Schachle | Option | 52,500 | 0.93 | — |
| Joseph Schachle | Option | 137,500 | 2.79 | — |
| Magrath | RSU | 200,000 | — | 402,000 |
| Magrath | Option | 275,000 | 2.87 | — |
| Magrath | RSU | 330,697 | — | 664,701 |
| Magrath | Option | 330,697 | 0.93 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Cam GallagherIndependent · Board Chair · Compensation Committee (Chair) · Nominating and Corporate Governance Committee | $104,000 | $141,859 | $50,108 | — | $0 | $295,967 |
| Sean AinsworthIndependent · Audit Committee · Compensation Committee | 84,500 | 75,529 | 50,108 | — | 0 | 210,137 |
| Richard RodgersIndependent · Audit Committee (Chair) | 63,813 | 75,529 | 50,108 | — | 0 | 189,450 |
| Dr. James S. ManusoIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair) | 62,000 | 76,809 | 50,108 | — | 0 | 188,917 |
| Susan K. BentonIndependent · Compensation Committee · Nominating and Corporate Governance Committee | 54,500 | 75,529 | 50,108 | — | 0 | 180,137 |
| Dr. Adrienne GravesIndependent · Nominating and Corporate Governance Committee | 45,806 | 75,529 | 50,108 | — | 0 | 171,443 |
| Dr. Jean BennettNot independent · Governance | 42,000 | 76,395 | 50,108 | — | 0 | 168,503 |
| Dr. George MagrathEmployee director · Governance | — | — | — | — | — | 0 |
| Dr. Benjamin R. YerxaEmployee director · Governance | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $42,000 |
|---|---|
| Annual equity retainer | $120,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $456,619 |
| Equity awards (grant-date value) | $597,179 |
| All other compensation | $0 |
| Total cost of the board | $1,053,798 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Opus Genetics as a peer
Companies that benchmark against IRD
No companies currently name IRD as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocugen, Inc. | 2025 | Shankar Musunuri | $757,900 | $2,194,445 | $1,385,871 | $0 | $4,841,822 |
| 2 | Aldeyra Therapeutics, Inc. | 2025 | Todd Brady | 700,000 | 0 | 3,801,379 | 189,000 | 4,704,179 |
| 3 | Adverum Biotechnologies, Inc. | 2024 | Laurent Fischer | 691,795 | 171,363 | 2,839,252 | 415,080 | 4,131,290 |
| 4 | Aura Biosciences, Inc. | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 5 | Annexon, Inc. | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 6 | Lineage Cell Therapeutics, Inc. | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 7 | 4D Molecular Therapeutics, Inc. | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 8 | Opus Genetics | 2025 | George Magrath | 598,000 | 307,548 | 212,045 | 361,790 | 1,493,383 |
| — | Outlook Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Opus Genetics | not disclosed | not disclosed | not disclosed | Anderson Pay Advisors, LLC |
| 4D Molecular Therapeutics, Inc. | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Adverum Biotechnologies, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Aldeyra Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Annexon, Inc. | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Aura Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Lineage Cell Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Anderson |
| Ocugen, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners LLC |
| Outlook Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-20 | 34,862,743 | 259,749 | 110,779 | 99.26% | Passed |
| 2025 | 2025-04-30 | 20,400,277 | 3,330,593 | 507,116 | 84.17% | Passed |
| 2024 | 2024-06-11 | 5,557,319 | 3,310,180 | 165,621 | 61.52% | Passed |
| 2021 | 2021-06-07 | 4,054,791 | 95,027 | 57,312 | 97.71% | Passed |
| 2017 | 2017-04-11 | 82,573,930 | 12,908,813 | 8,988,524 | 86.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-04-20 | 99.26%a |
| 2025 | 2025-04-30 | 84.17%b |
| 2024 | 2024-06-11 | 61.52%c |
a. Approved under the standard stated in the filing — “Proposal No. 3 Approval, on an advisory basis, of the compensation of the Company's named executive officers -- The affirmative vote of the holders of the majority of voting power of the shares present or represented by proxy at the Annual Meeting and entitled to vote on this proposal is required to approve this proposal. | Abstentions: An abstention has the same effect as a vote "against" this proposal. Broker discretionary voting is not permitted. Broker non-votes, if any, will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “3 Approval of Compensation for Named Executive Officers The affirmative vote of the holders of the majority of voting power of the shares virtually present or represented by proxy at the Annual Meeting and entitled to vote on this proposal is required to approve the proposal. || Abstentions: An abstention has the same effect as a vote "against" this proposal.”.
c. Approved under the standard stated in the filing — “ An abstention has the same effect as a vote "against" this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (25 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, George Magrath. DEF 14A, filed 2026-03-23. Section “Executive Compensation”. As printed: 1,493,383. View filing ↗
- Section 01, Ashwath Jayagopal. DEF 14A, filed 2026-03-23. Section “Executive Compensation”. As printed: 764,848. View filing ↗
- Section 01, Joseph Schachle. DEF 14A, filed 2026-03-23. Section “Executive Compensation”. As printed: 718,408. View filing ↗
- Section 08, Cam Gallagher. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 295,967. View filing ↗
- Section 08, Sean Ainsworth. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 210,137. View filing ↗
- Section 08, Richard Rodgers. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 189,450. View filing ↗
- Section 08, Dr. James S. Manuso. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 188,917. View filing ↗
- Section 08, Susan K. Benton. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 180,137. View filing ↗
- Section 08, Dr. Adrienne Graves. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 171,443. View filing ↗
- Section 08, Dr. Jean Bennett. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 168,503. View filing ↗
- Section 08, Dr. George Magrath. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Dr. Benjamin R. Yerxa. DEF 14A, filed 2026-03-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-04-22. Item 5.07 · say-on-pay result. As reported: 99.26% (votes for as printed: 34,862,743). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-01. Item 5.07 · say-on-pay result. As reported: 84.17% (votes for as printed: 20,400,277). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-13. Item 5.07 · say-on-pay result. As reported: 61.52% (votes for as printed: 5,557,319). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 456,619 + equity 597,179 + all other 0 = 1,053,798, summed across the director compensation table rows.
- Ocugen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ocugen, Inc.'s own proxy. As printed: 4,841,822. View filing ↗
- Aldeyra Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Aldeyra Therapeutics, Inc.'s own proxy. As printed: 4,704,179. View filing ↗
- Adverum Biotechnologies, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Adverum Biotechnologies, Inc.'s own proxy. As printed: 4,131,290. View filing ↗
- Aura Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences, Inc.'s own proxy. As printed: 3,956,167. View filing ↗
- Annexon, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 3,579,202. View filing ↗
- Lineage Cell Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Lineage Cell Therapeutics, Inc.'s own proxy. As printed: 2,111,170. View filing ↗
- 4D Molecular Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in 4D Molecular Therapeutics, Inc.'s own proxy. As printed: 2,051,343. View filing ↗
- Opus Genetics (subject), Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Opus Genetics's own proxy. As printed: 1,493,383. View filing ↗